Safety Net
Posted on June 17, 2013 by A&U in LifeGuide, Treatment Horizons
Treatment Horizons by Chael Needle A nonprofit creates a new support system for the uninsured Joining Merck and ViiV Healthcare, Gilead Sciences is now supporting and participating in a new patient assistance program (PAP) that provides individuals living with HIV/AIDS and in treatment with a singular portal to free medications. Launched in the summer of [...]
Cuts to Healthcare
Posted on May 28, 2013 by A&U in LifeGuide, Treatment Horizons
Treatment Horizons by Chael Needle Hill & Mountain? Weakened federal support of HIV/AIDS services puts our health at risk President Obama’s fiscal year 2014 budget plan includes increases in funding for ADAP and the various components of Ryan White and sustained or increased funding for CDC prevention services, HOPWA, and NIH and the Veterans Administration. [...]
HIV Latency & HDACs
Posted on April 18, 2013 by A&U in LifeGuide, Treatment Horizons
Hide and Seek Led by Dr. Daria Hazuda, researchers tackle HIV latency with HDAC inhibitors by Chael Needle With all the talk around viral suppression, it may seem odd at first to hear that researchers are looking for agents that reactivate HIV in the body, but not once you remember that HIV has the ability [...]
Skin Cancers Revisited
Posted on April 3, 2013 by A&U in LifeGuide, Treatment Horizons
Sun Blocked A new study examines non-melanoma skin cancers & HIV by Chael Needle In the pre-HAART era, an AIDS diagnosis or even an HIV-positive diagnosis illuminated a particular set of urgent health concerns. Now that treatment often affords longer life for HIV-positive individuals, HIV disease is increasingly intersecting with health concerns related to lifestyle [...]
Bathroom Reading
Posted on March 1, 2013 by A&U in LifeGuide, Treatment Horizons
A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in adult patients living with HIV/AIDS who are also on antiretroviral therapy. Available in early 2013 from Salix Pharmaceuticals, which develops and markets [...]
Monoclonal Antibodies
Posted on December 25, 2012 by A&U in LifeGuide, Treatment Horizons
Stronger Punch? Monoclonal antibodies provide new hope for easier dosing by Jeannie Wraight With multi-drug, once-a-day therapies now available for use, the push for additional easier to manage and tolerate HIV drug regimens has never been greater. Whereas Atripla and Stribild offer simple dosing, ARV-related toxicities and side effects continue to make drug adherence difficult. [...]
TB Announced
Posted on December 13, 2012 by A&U in LifeGuide, Treatment Horizons
A not-for-profit biotech helps energize the future of TB vaccine R&D by Chael Needle According to the World Health Organization, tuberculosis is the most common illness in individuals living with HIV and is the cause of one in four HIV-related deaths. While TB/HIV co-infection has made an impact, particularly in sub-Saharan Africa, TB has a devastating [...]
Not So Complicated
Posted on November 19, 2012 by A&U in LifeGuide, Treatment Horizons
Alisson Sombredero, MD, offers to physicians compelling approaches to HIV care by Chael Needle Alisson Sombredero, MD, is more than two months into her fellowship and couldn’t be more pleased: “It’s fantastic. I’ve learned so much and I have already been exposed to so many cases, so it’s been amazing.” Awarded a 2012 Minority Clinical [...]
Listen with Care
Posted on October 8, 2012 by A&U in LifeGuide, Treatment Horizons
Natasha Travis, MD, helps shape the HIV learning curve for physicians and patients by Chael Needle Awarded a 2012 Minority Clinical Fellowship by the HIV Medicine Association, Natasha Travis, MD, is tackling head-on the disproportionate impact of HIV infection on minorities. She is currently completing her fellowship at Emory University, the Ponce de Leon Clinic [...]
Expanded Portfolio
Posted on September 4, 2012 by A&U in LifeGuide, Treatment Horizons
A new study reports on the drug-drug interaction between pitavastatin and a common PI combo by Chael Needle Last year, A&U reported on a study that demonstrated minimal drug-drug interactions between Kowa Pharmaceuticals’ Livalo, or pitavastatin, and the anti-HIV protease inhibitor (PI) combination lopinavir/ritonavir. A pharmacokinetic study presented at last month’s International AIDS Conference shows [...]
